317 related articles for article (PubMed ID: 16633917)
1. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States).
Li CI; Malone KE; Daling JR
Cancer Causes Control; 2006 Jun; 17(5):695-703. PubMed ID: 16633917
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
[TBL] [Abstract][Full Text] [Related]
3. Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies.
Enger SM; Ross RK; Paganini-Hill A; Carpenter CL; Bernstein L
Cancer Epidemiol Biomarkers Prev; 2000 Jul; 9(7):681-7. PubMed ID: 10919738
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer risk with postmenopausal hormonal treatment.
Collins JA; Blake JM; Crosignani PG
Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effect between alcohol and estrogen replacement therapy on risk of breast cancer differs by estrogen/progesterone receptor status in the Iowa Women's Health Study.
Gapstur SM; Potter JD; Drinkard C; Folsom AR
Cancer Epidemiol Biomarkers Prev; 1995 Jun; 4(4):313-8. PubMed ID: 7655324
[TBL] [Abstract][Full Text] [Related]
6. Unopposed estrogen therapy and the risk of invasive breast cancer.
Chen WY; Manson JE; Hankinson SE; Rosner B; Holmes MD; Willett WC; Colditz GA
Arch Intern Med; 2006 May; 166(9):1027-32. PubMed ID: 16682578
[TBL] [Abstract][Full Text] [Related]
7. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.
Kerlikowske K; Miglioretti DL; Ballard-Barbash R; Weaver DL; Buist DS; Barlow WE; Cutter G; Geller BM; Yankaskas B; Taplin SH; Carney PA
J Clin Oncol; 2003 Dec; 21(23):4314-21. PubMed ID: 14645420
[TBL] [Abstract][Full Text] [Related]
8. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women.
Tamimi RM; Hankinson SE; Chen WY; Rosner B; Colditz GA
Arch Intern Med; 2006 Jul; 166(14):1483-9. PubMed ID: 16864758
[TBL] [Abstract][Full Text] [Related]
9. Statins and breast cancer in postmenopausal women without hormone therapy.
Eaton M; Eklof J; Beal JR; Sahmoun AE
Anticancer Res; 2009 Dec; 29(12):5143-8. PubMed ID: 20044629
[TBL] [Abstract][Full Text] [Related]
10. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
[TBL] [Abstract][Full Text] [Related]
11. Alcohol consumption and breast cancer risk in the Women's Health Study.
Zhang SM; Lee IM; Manson JE; Cook NR; Willett WC; Buring JE
Am J Epidemiol; 2007 Mar; 165(6):667-76. PubMed ID: 17204515
[TBL] [Abstract][Full Text] [Related]
12. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype.
McCullough ML; Patel AV; Patel R; Rodriguez C; Feigelson HS; Bandera EV; Gansler T; Thun MJ; Calle EE
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):73-9. PubMed ID: 18187388
[TBL] [Abstract][Full Text] [Related]
13. Do breast cancer risk factors modify the association between hormone therapy and mammographic breast density? (United States).
Aiello EJ; Buist DS; White E
Cancer Causes Control; 2006 Dec; 17(10):1227-35. PubMed ID: 17111253
[TBL] [Abstract][Full Text] [Related]
14. Population attributable risk of invasive postmenopausal breast cancer and breast cancer subtypes for modifiable and non-modifiable risk factors.
Barnes BB; Steindorf K; Hein R; Flesch-Janys D; Chang-Claude J
Cancer Epidemiol; 2011 Aug; 35(4):345-52. PubMed ID: 21159569
[TBL] [Abstract][Full Text] [Related]
15. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study.
Chang SC; Lacey JV; Brinton LA; Hartge P; Adams K; Mouw T; Carroll L; Hollenbeck A; Schatzkin A; Leitzmann MF
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):723-30. PubMed ID: 17416763
[TBL] [Abstract][Full Text] [Related]
16. Hormone therapy and breast cancer: what factors modify the association?
Gertig DM; Fletcher AS; English DR; Macinnis RJ; Hopper JL; Giles GG
Menopause; 2006; 13(2):178-84. PubMed ID: 16645531
[TBL] [Abstract][Full Text] [Related]
17. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study.
Kahán Z; Gardi J; Nyári T; Földesi I; Hajnal-Papp R; Ormándi K; Lázár G; Thurzó L; Schally AV
Int J Oncol; 2006 Jul; 29(1):193-200. PubMed ID: 16773200
[TBL] [Abstract][Full Text] [Related]
18. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
[TBL] [Abstract][Full Text] [Related]
19. Menopausal hormone therapy and breast cancer phenotype: does dose matter?
Garwood ER; Kumar AS; Shim V
Ann Surg Oncol; 2008 Sep; 15(9):2526-32. PubMed ID: 18618187
[TBL] [Abstract][Full Text] [Related]
20. Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status.
Bardia A; Hartmann LC; Vachon CM; Vierkant RA; Wang AH; Olson JE; Sellers TA; Cerhan JR
Arch Intern Med; 2006 Dec 11-25; 166(22):2478-83. PubMed ID: 17159013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
